MediciNova, Inc. (MNOV) News

MediciNova, Inc. (MNOV): $2.48

-0.05 (-1.98%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MNOV to Watchlist
Sign Up

Industry: Biotech


Ranked

of 459

in industry

Filter MNOV News Items

MNOV News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

MNOV News Highlights

  • For MNOV, its 30 day story count is now at 14.
  • Over the past 27 days, MNOV's stories per day has been in a clear downtrend, falling by about 0.46 per 4 days.
  • MN and AUD are the most mentioned tickers in articles about MNOV.

Latest MNOV News From Around the Web

Below are the latest news stories about Medicinova Inc that investors may wish to consider to help them evaluate MNOV as an investment opportunity.

MediciNova Announces MN-166 (ibudilast) Identified as Promising Pharmacotherapy for Alcohol Use Disorder in Drugs

LA JOLLA, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced MN-166 (ibudilast) was discussed as one of the promising pharmacological agents for the treatment of alcohol use disorder (AUD) in the journal Drugs. The publication entitled “Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder,” co-authored by Me

Yahoo | February 22, 2022

The past three years for MediciNova (NASDAQ:MNOV) investors has not been profitable

Investing in stocks inevitably means buying into some companies that perform poorly. Long term MediciNova, Inc...

Yahoo | February 14, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Rise and shine, trader!

William White on InvestorPlace | February 1, 2022

MediciNova nabs new patent in Korea for MN-001 for treatment of blood cholesterol

MediciNova (MNOV) received a new patent from the Korean Intellectual Property Office which covers MN-001 (tipelukast) for the treatment of hypertriglyceridemia, hypercholesterolemia,

Seeking Alpha | February 1, 2022

MediciNova Receives a New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Korea

LA JOLLA, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a new patent from the Korean Intellectual Property Office which covers MN-001 (tipelukast) for the treatment of hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia. Once issued, the patent maturing from this allowed patent appli

Yahoo | February 1, 2022

MediciNova stock jumps after securing Canada patent for MN-001/002 for hepatic ballooning

MediciNova (MNOV) gains 9.7% premarket after receiving a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers

Seeking Alpha | January 31, 2022

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in Canada

LA JOLLA, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for hepatic ballooning. Once issued, the patent maturing from this a

Yahoo | January 31, 2022

MediciNova receives new European patent for ibudilast for alcohol use disorder

MediciNova (MNOV) has received a Notice of Intention to Grant from the European Patent Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of

Seeking Alpha | January 27, 2022

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Alcohol Use Disorder in Europe

LA JOLLA, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Intention to Grant from the European Patent Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of alcohol use disorder. Once issued, the patent maturing from this allowed patent application is e

Yahoo | January 27, 2022

MediciNova secures new European patent for MN-001 and MN-002 for hepatic ballooning

MediciNova (MNOV) that it has received a Notice of Intention to Grant from the European Patent Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a

Seeking Alpha | January 26, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5491 seconds.